Single Arm Study of Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

N/ACompletedNCT05211921

Karo Pharma AB50 enrolled

Overview

Open, single arm trial that intends to confirm the safety and efficacy of Multi-Gyn ActiGel Plus for treatment of Bacterial Vaginosis. Adult women will be diagnosed by the gynaecologist based on the Amsel criteria at day 0. They will use the product for 7 days and will come to the practice at day 21. The primary endpoint is the clinical cure rate of Bacterial Vaginosis at 3 weeks after start of treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bacterial Vaginosis

Interventions

Multi-Gyn ActiGel PlusDEVICE

vaginal gel

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women diagnosed with BV (3 out of 4 Amsel criteria positive, with at least presence of clue cells (\>20%) * Women of childbearing potential * Aged \>18 years * Signed written informed consent form * Willing to comply to the follow-up schedule Exclusion Criteria: * Current clinically manifest of sexually transmitted gynecologically infection, genital tract infection, vulvovaginal candidosis or aerobic vaginitis * Presence of Trichomonas and/or Candida Albicans in vaginal smear during examination of the smears for Amsel criteria (clue cells detection) * Current genital malignancies * Chemotherapy for any reason in last 6 months * Radiotherapy in the genitourinary system in the last 12 months * Use of antibiotics for any reason in the last 14 days * Pregnancy or currently attempting to conceive * Lactation * Use of other treatment for vaginal conditions during the course of the clinical investigation * Known allergies to ingredients of the product * Concomitant medication for treatment of vaginal infections, or other use of intravaginal medication during the course of the clinical investigation

Locations (1)

Eurofins Dermascan Poland

Gdansk, Poland

Outcomes

Primary Outcomes

The primary endpoint is clinical cure rate of BV at 3 weeks after start of treatment (Visit 2).

Primary endpoint is to demonstrate a responder rate significantly higher than 30% in treatment of bacterial vaginosis at 3 weeks after start of treatment using a two tailed binomial test.

Time frame: 3 weeks after start of treatment

Secondary Outcomes

Relief of vaginal symptoms related to BV at Visit 2

It is based on 0-10 point scale ( 0 is no improvement at all and 10 is the highest improvement)) . It is considered significant if the the score improvement is \> 1.

Time frame: 3 weeks after start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.